Tag: iPSCs

Creative Bioarray Built Professional Cell Reprogramming Services with Cutting-edge Technologies to Accelerate Drug Development and Research

Creative Bioarray announced the release of its professional cell reprogramming services with cutting-edge technologies to accelerate drug development and research. New York, USA – January 24, 2022 – Cell culture platform, the division of Creative Bioarray, focuses on developing complete cell culture solutions with plenty of choices for the next…

Continue Reading Creative Bioarray Built Professional Cell Reprogramming Services with Cutting-edge Technologies to Accelerate Drug Development and Research

PostDoc iPSCs for toxicology (m/w/d) – Biberach

OUR COMPANY At Boehringer Ingelheim we develop breakthrough therapies and innovative healthcare solutions in areas of unmet medical need for both humans and animals. As a family owned company, we focus on long-term performance. We believe that, if we have talented and ambitious people who are passionate about innovation, there…

Continue Reading PostDoc iPSCs for toxicology (m/w/d) – Biberach

Pluristyx, panCELLa, and Implant Therapeutics Announce a Strategic Alliance to Manufacture and Distribute Genetically Modified, Clinical-grade Human-induced Pluripotent Stem Cells

SEATTLE–(BUSINESS WIRE)–Pluristyx, Inc., an advanced therapy tools and services biotechnology company, panCELLa, a privately held biotechnology company, and Implant Therapeutics, a developer of genetically engineered stem cells, today announced they have entered into a manufacturing and distribution strategic alliance that offers cell therapy companies streamlined access to the next generation…

Continue Reading Pluristyx, panCELLa, and Implant Therapeutics Announce a Strategic Alliance to Manufacture and Distribute Genetically Modified, Clinical-grade Human-induced Pluripotent Stem Cells

Applications of iPSCs in Gaucher Disease and other rare sphingolipidoses

Chapter contents Book contents Volume 16 in Advances in Stem Cell Biology 2022, Pages 197-224 doi.org/10.1016/B978-0-323-85767-3.00001-3Get rights and content Abstract In this chapter, an overview of various applications of induced pluripotent cells (iPSCs) is given. This chapter focuses on the uses of iPSCs in inherited diseases and, particularly, in the…

Continue Reading Applications of iPSCs in Gaucher Disease and other rare sphingolipidoses

Generation of a human iPSC line CIPi001-A from a benign familial infantile epilepsy patient related 16p11.2 deletion

doi.org/10.1016/j.scr.2021.102634Get rights and content Abstract The features of 16p11.2 deletion phenotype is developmental delay, intellectual disability, and autism spectrum disorder. Seizures are observed in approximately 20% of individuals with the microdeletion. Induced pluripotent stem cells (iPSCs) were generated from erythroblasts obtained from a child diagnosed with benign familial infantile epilepsy,…

Continue Reading Generation of a human iPSC line CIPi001-A from a benign familial infantile epilepsy patient related 16p11.2 deletion

NIH researchers develop first stem cell model of albinism to study related eye conditions

News Release Tuesday, January 11, 2022 Use of patient-derived stem cells will enable high-throughput drug screening for potential therapeutics. Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model’s development is described in…

Continue Reading NIH researchers develop first stem cell model of albinism to study related eye conditions

Applications of human iPSCs for disease modeling and screening

The development of physiologically relevant human models for neurological diseases remains a challenge for pre-clinical drug discovery. With the emergence of human induced pluripotent stem cell (hiPSC) technology, it is now possible to design and manufacture cell types that are critical players in neural disease pathogenesis, such as neurons, astrocytes…

Continue Reading Applications of human iPSCs for disease modeling and screening

Rare Diseases Are Focus of Latest Yale Journal of Biology and Medicine

The Yale Journal of Biology and Medicine’s (YJBM’s) December 2021 issue on rare disease has been published on PubMed Central. This focus issue features articles on just a few of the estimated 7,000 rare diseases people in the world experience. As we get closer to Rare Disease Day on February…

Continue Reading Rare Diseases Are Focus of Latest Yale Journal of Biology and Medicine

Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences

H.C. Wainwright BioConnect 2022 Conference January 10-13, 2022 Biotech Showcase Virtual Conference January 17-19, 2022 CRANFORD, N.J., Jan. 4, 2022 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on…

Continue Reading Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences

Investigating changes in the proteostasis capabilities of iPSC-neurons during development and in FTD using iPSC-neurons with MAPT mutations

This article was originally published here Alzheimers Dement. 2021 Dec;17 Suppl 2:e058308. doi: 10.1002/alz.058308. ABSTRACT BACKGROUND: Mutations in microtubule-associated protein tau (MAPT) gene are causative of Frontotemporal Dementia (FTD). Many of the features associated with the development of tau pathology, e.g high levels of tau phosphorylation, are also present in…

Continue Reading Investigating changes in the proteostasis capabilities of iPSC-neurons during development and in FTD using iPSC-neurons with MAPT mutations

Generation of Primordial Germ Cell-like Cells from iPSCs Derived from Turner Syndrome Patients

Figure 6 Dynamics of pluripotent and germ cells markers during hPGCLCs -TS induction. ( A… Figure 6 Dynamics of pluripotent and germ cells markers during hPGCLCs -TS induction. (A) Schematic protocol used to generate hPGCLCs. (B) hiPSCs-TS (p20), hEpiLC-TS (D.2), and hPGCLCs-TS (D.6) quantification of the relative expression of OCT4,…

Continue Reading Generation of Primordial Germ Cell-like Cells from iPSCs Derived from Turner Syndrome Patients

iPSCs and DRGs: stepping stones to new pain therapies

doi.org/10.1016/j.molmed.2021.11.005Get rights and content Highlights Voltage-gated sodium (NaV) channels are key drivers of pain in humans and contribute to neuronal excitability and have been regarded as opportune therapeutic targets. The limited success of developing pain therapies targeting NaV channels may reflect the limitations of preclinical screening systems, as heterologous cell…

Continue Reading iPSCs and DRGs: stepping stones to new pain therapies

Rapid generation of ventral spinal cord-like astrocytes from human iPSCs for modeling non-cell autonomous mechanisms of lower motor neuron disease

Abstract Background: Astrocytes play important roles in the function and survival of neuronal cells. Dysfunctions of astrocytes are associated with numerous disorders and diseases of the nervous system, including motor neuron diseases such as amyotrophic lateral sclerosis (ALS). Human induced pluripotent stem cell (iPSC)-based approaches are becoming increasingly important for…

Continue Reading Rapid generation of ventral spinal cord-like astrocytes from human iPSCs for modeling non-cell autonomous mechanisms of lower motor neuron disease

Fate Therapeutics Highlights Positive Durability of

6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autologous CAR T-cell Therapy Achieve Complete Response…

Continue Reading Fate Therapeutics Highlights Positive Durability of

Induced Pluripotent Stem Cells Detection via Ensemble Yolo Network

Induced pluripotent stem cells (iPSCs) have huge potential in regenerative medicine research and industrial applications. However, building automatic method without using cell staining technique for iPSCs identification is an important challenge. To improve the efficiency of producing iPSCs, we build an accurate and noninvasive iPSCs colonies detection method via ensemble…

Continue Reading Induced Pluripotent Stem Cells Detection via Ensemble Yolo Network

Stomach organoid created from multiple stem cell types | 2021-12-10

A group of scientists at the Cincinnati Children’s Hospital has used separate lines of human induced pluripotent stem cells (iPSCs) to create stomach organoids with a three-layered structure and gastric function such as smooth muscle contraction and glandular secretion. The team reported its results in the December 2021, issue of…

Continue Reading Stomach organoid created from multiple stem cell types | 2021-12-10

An Optimized Culture Medium for Induced Pluripotent Stem Cells

In 2006, Kazutoshi Takahashi and Shinya Yamanaka made a revolutionary breakthrough when they reprogrammed terminally differentiated, lineage-restricted adult somatic cells into a pluripotent state via the expression of transcription factors Oct4, Sox2, Klf4, and c-Myc.1 Now, researchers can differentiate reprogrammed induced pluripotent stem cells (iPSCs) into any cell type and…

Continue Reading An Optimized Culture Medium for Induced Pluripotent Stem Cells

Doctoral student finds alternative cell option for organs-on-chips — ScienceDaily

Organ-on-a-chip technology has provided a push to discover new drugs for a variety of rare and ignored diseases for which current models either don’t exist or lack precision. In particular, these platforms can include the cells of a patient, thus resulting in patient-specific discovery. As an example, even though sickle…

Continue Reading Doctoral student finds alternative cell option for organs-on-chips — ScienceDaily

Researchers Make New iPSC Models of Friedreich’s Ataxia

A team of scientists at Koc University in Turkey has created three new cell models of Friedreich’s ataxia (FA) derived from patients with repeat expansions in their FXN gene. The models “will facilitate studies to understand molecular mechanisms related to FRDA [Friedreich’s ataxia] pathology [disease processes] as well as therapeutic investigations…

Continue Reading Researchers Make New iPSC Models of Friedreich’s Ataxia

MD Anderson research highlights 9 December

ATLANTA ― The University of Texas MD Anderson Cancer Center‘s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features presentations at the 2021 American Society of Hematology (ASH) Annual Meeting on innovative targeted therapies, new combination approaches, and novel…

Continue Reading MD Anderson research highlights 9 December

Hyperexcitability and Pharmacological Responsiveness of Cortical Neurons Derived from Human iPSCs Carrying Epilepsy-Associated Sodium Channel Nav1.2-L1342P Genetic Variant

Abstract With the wide adoption of genomic sequencing in children having seizures, an increasing number of SCN2A genetic variants have been revealed as genetic causes of epilepsy. Voltage-gated sodium channel Nav1.2, encoded by gene SCN2A, is predominantly expressed in the pyramidal excitatory neurons and supports action potential (AP) firing. One…

Continue Reading Hyperexcitability and Pharmacological Responsiveness of Cortical Neurons Derived from Human iPSCs Carrying Epilepsy-Associated Sodium Channel Nav1.2-L1342P Genetic Variant

How Artificial Intelligence Can Be Used To Augment Stem Cell Therapy In Hospitals

Stem cell therapy comes with its own set of challenges despite being a revolutionary discovery in modern healthcare. As we know, AI has several applications in the deep and diverse field of healthcare. So, stem cell AI’s incredible capabilities can overcome those challenges and truly improve stem cell therapy in…

Continue Reading How Artificial Intelligence Can Be Used To Augment Stem Cell Therapy In Hospitals

Scientific webinars on SelectScience

Genome engineering has revolutionized medical research through the ability to precisely edit the DNA sequence of cells. In combination with human induced pluripotent stem cells (hiPSCs), editing the genome can provide unprecedented insight into disease-causing mechanisms on a patient and tissue-specific basis. A major challenge, however, is the efficient generation…

Continue Reading Scientific webinars on SelectScience

CRISPR-Engineered Cells Release Drug in Response to Inflammation When Implanted into Mice

Source: Science Photo Library/Getty Images Researchers at Washington University School of Medicine in St. Louis have used CRISPR-Cas9 genome editing to engineer induced pluripotent stem cells (iPSCs) that can be implanted subcutaneously to deliver an anticytokine biologic drug in response to inflammation caused by rheumatoid arthritis. When implanted into a…

Continue Reading CRISPR-Engineered Cells Release Drug in Response to Inflammation When Implanted into Mice

New Techniques and Complex Models

CRISPR systems that rely on inactivated Cas enzymes—that is, dead Cas (dCas) enzymes—never looked more alive. They harness the targeting power associated with CRISPR—but not the double-strand cuts. As such, they give researchers new ways to interrogate and manipulate gene function. Possibilities include CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa)…

Continue Reading New Techniques and Complex Models

Editas Medicine Presents Data on New SLEEK Gene Editing

SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells Data support SLEEK as an optimized approach to develop next generation cell therapy medicines CAMBRIDGE, Mass., Aug. 20, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today…

Continue Reading Editas Medicine Presents Data on New SLEEK Gene Editing

Python fast way to get ONLY MAIN metadata for GSE ? (not walking through thousands underlying GSM-samples : slow or even endless)

  Not Python but using EntrezDirect you can get: $ esearch -db bioproject -query “GSE118723” | esummary | xtract -pattern DocumentSummary -element Project_Description Quantification of gene expression levels at the single cell level has revealed that gene expression can vary substantially even across a population of homogeneous cells. However, it…

Continue Reading Python fast way to get ONLY MAIN metadata for GSE ? (not walking through thousands underlying GSM-samples : slow or even endless)